Convert SwissBorg BORG to VitaStem VITASTEM

What is SwissBorg? SwissBorg’s flagship product is an all-encompassing crypto management app for retail users. It enables them to on & off ramp, exchange crypto and fiat, earn yield, buy bundles of crypto and access its launchpad investment opportunities. SwissBorg started in the ICO era of 2017 and has over 1 million registered users as of 2024. The app’s products range from on/off ramp, CEX & DEX aggregator (MEX), staking and other passive income opportunities (Earn), cryptocurrency bundles (Thematics), and a launchpad & one-time opportunities (Alpha Early Deals) and more. SwissBorg users are also entitled to airdrops if they happen as it’s one the few centralised entities redistributing them directly to their users. What is BORG? BORG is essential to the SwissBorg experience as it unlocks additional utilities in the app. The more BORG users hold in the app, the more benefits they can unlock either through Premium Tiers or ad-hoc campaigns. Benefits include lower exchange fees, higher allocation in launchpads, higher yield on Earn strategies and increased voting power in referendums proposed by SwissBorg. When was SwissBorg Founded? The project was launched in Switzerland in 2017 and the ICO lasted from Dec 7th, 2017 to January 10th, 2018 where $50 million was raised to kickstart the project. In Q1 2023 SwissBorg performed a Series A, where 16,660 big and small individual investors raised a total of over 21 million Swiss Francs (CHF).

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.